Kevin Oliver

Kevin Oliver serves as the Chief Business Officer at Acadia Pharmaceuticals Inc. since July 2023, focusing on corporate and business development to advance therapeutics for neurologic, psychiatric, and rare diseases. Prior to this role, Kevin worked at Simcere Pharmaceutical Group from March 2020 to July 2023, where responsibilities included global operations and business development, significantly growing the team and enhancing capabilities across various functions. Kevin's extensive career includes leadership positions at Alcon and Merck, where initiatives included establishing industry-leading business development and licensing groups, negotiating high-value deals, and leading teams in innovative drug development efforts. Kevin holds a PhD in Neuroscience from the University of Cambridge and a BSc in Immunology & Molecular Biology from King's College London.